As previously announced on January 9, 2024, worldwide revenue for the full year 2023 is expected to be in the range of $1.295 – 1.297 billion, which includes a $15 million RELISTOR milestone achievement, compared with $0.935 billion for the full year 2022, which would represent an increase of approximately 38 – 39% over the prior year period, exceeding the Company’s previously issued guidance range of $1.255 – 1.270 billion.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LNTH:
- Lantheus announces acceptance of its first-to-file ANDA for generic LUTATHERA
- Perspective Therapeutics enters strategic agreements with Lantheus
- Lantheus expands radiopharmaceutical oncology pipeline via agreements
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
- Lantheus Reports Preliminary Fiscal Year 2023 Revenue
